Kiromic BioPharma up on positive FDA feedback for lung cancer therapy, job cuts
06/10/2022 13:50
** Kiromic BioPharma Inc's shares KRBP.O rise 47% to $0.40
before the bell
** KRBP says it receives a pre-clinical FDA feedback for its
therapy to treat patients with a type of lung cancer confirming
its development strategy urn:newsml:reuters.com:*:nBw26nnRna
** Co says it will use the feedback and recommendation of
submission for application to initiate trial, projected to
launch in Q1 2023
** Drug developer cuts workforce by 29%, removing 20
positions in the company, streamlining operation to focus on the
therapy
** Up to Wednesday's close, stock lost ~82% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site